Sirolimus for COVID-19
Sirolimus has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316 ,
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3 ,
A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992 ,
Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029 ,
Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802 (Table 2) ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.